177 related articles for article (PubMed ID: 36266502)
1. Novel Cross-Correction-Enabled Gene Therapy for CDKL5-Deficiency Disorder.
Nitschke F; Montalbano AP
Neurotherapeutics; 2022 Oct; 19(6):1878-1882. PubMed ID: 36266502
[No Abstract] [Full Text] [Related]
2. Expression of a Secretable, Cell-Penetrating CDKL5 Protein Enhances the Efficacy of Gene Therapy for CDKL5 Deficiency Disorder.
Medici G; Tassinari M; Galvani G; Bastianini S; Gennaccaro L; Loi M; Mottolese N; Alvente S; Berteotti C; Sagona G; Lupori L; Candini G; Baggett HR; Zoccoli G; Giustetto M; Muotri A; Pizzorusso T; Nakai H; Trazzi S; Ciani E
Neurotherapeutics; 2022 Oct; 19(6):1886-1904. PubMed ID: 36109452
[TBL] [Abstract][Full Text] [Related]
3. CDKL5 protein substitution therapy rescues neurological phenotypes of a mouse model of CDKL5 disorder.
Trazzi S; De Franceschi M; Fuchs C; Bastianini S; Viggiano R; Lupori L; Mazziotti R; Medici G; Lo Martire V; Ren E; Rimondini R; Zoccoli G; Bartesaghi R; Pizzorusso T; Ciani E
Hum Mol Genet; 2018 May; 27(9):1572-1592. PubMed ID: 29474534
[TBL] [Abstract][Full Text] [Related]
4. CDKL5 Deficiency Augments Inhibitory Input into the Dentate Gyrus That Can Be Reversed by Deep Brain Stimulation.
Hao S; Wang Q; Tang B; Wu Z; Yang T; Tang J
J Neurosci; 2021 Oct; 41(43):9031-9046. PubMed ID: 34544833
[TBL] [Abstract][Full Text] [Related]
5. Splicing Mutations Impairing CDKL5 Expression and Activity Can be Efficiently Rescued by U1snRNA-Based Therapy.
Balestra D; Giorgio D; Bizzotto M; Fazzari M; Ben Zeev B; Pinotti M; Landsberger N; Frasca A
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450582
[TBL] [Abstract][Full Text] [Related]
6. Aged heterozygous Cdkl5 mutant mice exhibit spontaneous epileptic spasms.
Mulcahey PJ; Tang S; Takano H; White A; Davila Portillo DR; Kane OM; Marsh ED; Zhou Z; Coulter DA
Exp Neurol; 2020 Oct; 332():113388. PubMed ID: 32585155
[TBL] [Abstract][Full Text] [Related]
7. Molecular and Synaptic Bases of CDKL5 Disorder.
Zhu YC; Xiong ZQ
Dev Neurobiol; 2019 Jan; 79(1):8-19. PubMed ID: 30246934
[TBL] [Abstract][Full Text] [Related]
8. Hypermotor-tonic-spasms seizure sequence related to CDKL5 deficiency disorder: a typical case.
Appendino JP
Epileptic Disord; 2022 Dec; 24(6):1127-1128. PubMed ID: 35934889
[No Abstract] [Full Text] [Related]
9. CDKL5 deficiency disorder: At the intersection between Rett syndrome and developmental epileptic encephalopathies.
Kaufmann WE
Dev Med Child Neurol; 2024 Apr; 66(4):410-411. PubMed ID: 37881024
[No Abstract] [Full Text] [Related]
10. Clinical manifestations and epilepsy treatment in Japanese patients with pathogenic CDKL5 variants.
Kobayashi Y; Tohyama J; Takahashi Y; Goto T; Haginoya K; Inoue T; Kubota M; Fujita H; Honda R; Ito M; Kishimoto K; Nakamura K; Sakai Y; Takanashi JI; Tanaka M; Tanda K; Tominaga K; Yoshioka S; Kato M; Nakashima M; Saitsu H; Matsumoto N
Brain Dev; 2021 Apr; 43(4):505-514. PubMed ID: 33436160
[TBL] [Abstract][Full Text] [Related]
11. Dopaminergic loss of cyclin-dependent kinase-like 5 recapitulates methylphenidate-remediable hyperlocomotion in mouse model of CDKL5 deficiency disorder.
Jhang CL; Lee HY; Chen JC; Liao W
Hum Mol Genet; 2020 Aug; 29(14):2408-2419. PubMed ID: 32588892
[TBL] [Abstract][Full Text] [Related]
12. CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures.
Wang HT; Zhu ZA; Li YY; Lou SS; Yang G; Feng X; Xu W; Huang ZL; Cheng X; Xiong ZQ
Epilepsia; 2021 Feb; 62(2):517-528. PubMed ID: 33400301
[TBL] [Abstract][Full Text] [Related]
13. Clinical evolution and epilepsy outcome in three patients with CDKL5-related developmental encephalopathy.
Bernardo P; Ferretti A; Terrone G; Santoro C; Bravaccio C; Striano S; Coppola A; Striano P
Epileptic Disord; 2019 Jun; 21(3):271-277. PubMed ID: 31225800
[TBL] [Abstract][Full Text] [Related]
14. Aminoglycoside drugs induce efficient read-through of
Fazzari M; Frasca A; Bifari F; Landsberger N
RNA Biol; 2019 Oct; 16(10):1414-1423. PubMed ID: 31232219
[TBL] [Abstract][Full Text] [Related]
15. CDKL5 Deficiency Disorder: Some Lessons Learned 20 Years After the First Description.
Pestana Knight EM; Olson HE
Am J Intellect Dev Disabil; 2024 Mar; 129(2):101-109. PubMed ID: 38411242
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-Dependent Kinase-Like 5 (CDKL5): Possible Cellular Signalling Targets and Involvement in CDKL5 Deficiency Disorder.
Katayama S; Sueyoshi N; Inazu T; Kameshita I
Neural Plast; 2020; 2020():6970190. PubMed ID: 32587608
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder.
Fuchs C; Gennaccaro L; Ren E; Galvani G; Trazzi S; Medici G; Loi M; Conway E; Devinsky O; Rimondini R; Ciani E
Neuropharmacology; 2020 May; 167():107746. PubMed ID: 31469994
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review.
Olson HE; Demarest ST; Pestana-Knight EM; Swanson LC; Iqbal S; Lal D; Leonard H; Cross JH; Devinsky O; Benke TA
Pediatr Neurol; 2019 Aug; 97():18-25. PubMed ID: 30928302
[TBL] [Abstract][Full Text] [Related]
19. A GABA
Gennaccaro L; Fuchs C; Loi M; Roncacè V; Trazzi S; Ait-Bali Y; Galvani G; Berardi AC; Medici G; Tassinari M; Ren E; Rimondini R; Giustetto M; Aicardi G; Ciani E
Neurobiol Dis; 2021 Jun; 153():105304. PubMed ID: 33621640
[TBL] [Abstract][Full Text] [Related]
20. Increased DNA Damage and Apoptosis in CDKL5-Deficient Neurons.
Loi M; Trazzi S; Fuchs C; Galvani G; Medici G; Gennaccaro L; Tassinari M; Ciani E
Mol Neurobiol; 2020 May; 57(5):2244-2262. PubMed ID: 32002787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
